189 related articles for article (PubMed ID: 1283851)
1. Vinorelbine. A review of its antitumour activity in lung cancer.
Sørensen JB
Drugs; 1992; 44 Suppl 4():60-5; discussion 66-9. PubMed ID: 1283851
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine: a novel vinca alkaloid.
Toso C; Lindley C
Am J Health Syst Pharm; 1995 Jun; 52(12):1287-304; quizz 1340-1. PubMed ID: 7656116
[TBL] [Abstract][Full Text] [Related]
5. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Kubota K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
7. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group.
Goss GD; Logan DM; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):28-38. PubMed ID: 9765724
[TBL] [Abstract][Full Text] [Related]
8. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
9. In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16).
Roussakis C; Pouchus YF; Gratas C; Riou D; Dimou P; Dabouis G; Merle S; Verbist JF
Anticancer Drug Des; 1993 Apr; 8(2):165-71. PubMed ID: 8388219
[TBL] [Abstract][Full Text] [Related]
10. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
11. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
12. The current and future place of vinorelbine in cancer therapy.
Cvitkovic E; Izzo J
Drugs; 1992; 44 Suppl 4():36-45; discussion 66-9. PubMed ID: 1283849
[TBL] [Abstract][Full Text] [Related]
13. Update: vinorelbine (navelbine) in non-small cell lung cancer.
Crawford J
Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
Crawford J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer.
Jones SF; Burris HA
Ann Pharmacother; 1996 May; 30(5):501-6. PubMed ID: 8740332
[TBL] [Abstract][Full Text] [Related]
17. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.
Stuckler D; Singhal J; Singhal SS; Yadav S; Awasthi YC; Awasthi S
Cancer Res; 2005 Feb; 65(3):991-8. PubMed ID: 15705900
[TBL] [Abstract][Full Text] [Related]
18. Single-agent vinorelbine in the treatment of non-small cell lung cancer.
Wozniak AJ
Semin Oncol; 1999 Oct; 26(5 Suppl 16):62-6; discussion 71-2. PubMed ID: 10585010
[TBL] [Abstract][Full Text] [Related]
19. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.
Gauvin A; Bressolle F; Martineau P; Astre C; Pinguet F
Anticancer Res; 2002; 22(2A):905-12. PubMed ID: 12014670
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group.
Jassem J; Karnicka-Młodkowska H; van Pottelsberghe C; van Glabbeke M; Noseda MA; Ardizzoni A; Gozzelino F; Planting A; van Zandwijk N
Eur J Cancer; 1993; 29A(12):1720-2. PubMed ID: 8398301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
